Abstract:
BACKGROUND:European guidelines advocate the measurement of on-treatment hepatitis C virus (HCV) RNA in order to determine optimal therapy duration (response-guided therapy [RGT]) in patients with rapid virological response (RVR) or delayed virological response (DVR). Treatment response is highly dependent upon the extent of liver fibrosis yet there is little evidence quantifying the cost effectiveness of RGT particularly conditional upon fibrosis stage. OBJECTIVE:This study describes an economic model designed to assess the costs and benefits of RGT compared with standard duration of therapy (SDT) in hepatitis C virus genotype 1 patients. METHODS:A Markov cohort simulation model with lifetime perspective was developed to undertake a cost utility analysis of RGT in the UK. Patients entered the model at Metavir disease stages F0-F4, and progressed through these stages via age and duration of HCV infection-dependent transition probabilities. Treated patients were partitioned according to virological response and shortened or extended duration of therapy was applied following European guidelines. RESULTS:For all patients, SDT and RGT was associated with an increase of 2.14 and 2.20 QALYs and £2,374 and £2,270 costs, respectively, compared with no treatment. Overall, RGT was a dominant scenario being associated with a lower risk of complications, increased QALYs (0.08) and cost saving (£101). RGT across fibrosis stages was either highly cost effective or dominant; in all cases RGT was associated with an increase in QALYs, driven by a reduction in complications in DVR subjects and reduced exposure to treatment disutility in RVR subjects; costs were lower in F1 and F2 fibrosis stages. At a willingness-to-pay threshold of £20,000 per QALY, overall RGT across fibrosis stages F2-F4 were associated with the highest probability of being cost effective. At this threshold, the probability of reduced/extended therapy in RVR/DVR patients being cost effective is 0.35 and 0.88, respectively. CONCLUSIONS:This analysis suggests that the treatment of HCV genotype 1 patients in fibrosis stage F2 has the greatest potential for maximizing health benefit and cost saving within an RGT protocol. Predicting those patients most likely to respond to treatments is important from both a clinical and cost perspective and the tailoring of treatment duration with the current standard of care is likely to remain a priority for payers with budgetary constraints.
journal_name
Appl Health Econ Health Policyjournal_title
Applied health economics and health policyauthors
McEwan P,Kim R,Yuan Ydoi
10.1007/s40258-012-0002-0subject
Has Abstractpub_date
2013-02-01 00:00:00pages
53-63issue
1eissn
1175-5652issn
1179-1896journal_volume
11pub_type
杂志文章abstract::The Peristeen transanal irrigation system is intended to allow people with bowel dysfunction to flush out the lower part of the bowel as part of their bowel management strategy. Peristeen was the subject of an evaluation by the National Institute for Health and Care Excellence, through its Medical Technologies Evaluat...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-018-0447-x
更新日期:2019-02-01 00:00:00
abstract:BACKGROUND:As tuberculosis screening trends to targeting high-risk populations, knowing the cost effectiveness of such screening is vital to decision makers. OBJECTIVES:The purpose of this review was to compile cost-utility analyses evaluating latent tuberculosis infection (LTBI) screening in high-risk populations tha...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-015-0183-4
更新日期:2015-08-01 00:00:00
abstract:BACKGROUND:Community-based health insurance (CBHI) schemes have been introduced in low- and middle-income countries to increase health service utilization and provide financial protection from high healthcare expenditures. OBJECTIVE:We assess the impact of household size on decisions to enroll in CBHI and demonstrate ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-016-0222-9
更新日期:2016-04-01 00:00:00
abstract:BACKGROUND:Updated treatment guidelines for atrial fibrillation (AF) have been released by the National Institute for Health and Care Excellence (NICE) in the UK, and highlight a current shortfall in the prescription of anticoagulants to patients with AF for stroke prevention. OBJECTIVE:To design a budget impact model...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-015-0180-7
更新日期:2015-10-01 00:00:00
abstract:OBJECTIVES:To analyse the cost effectiveness of community-based case management for patients suffering from chronic obstructive pulmonary disease (COPD). METHODS:The study took place in the third largest municipality in Denmark and was conducted as a randomised controlled trial with 12 months of follow-up. A total of ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-016-0298-2
更新日期:2017-06-01 00:00:00
abstract:OBJECTIVE:Several EU countries are determining reimbursement prices of pharmaceuticals by cross-referencing prices of foreign countries. Our objective is to quantify the theoretical cross-border spill-over effects of cross-reference pricing schemes on pharmaceutical prices in the former EU-15 countries. METHODS:An ana...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/00148365-200605040-00005
更新日期:2006-01-01 00:00:00
abstract:BACKGROUND:Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia. OBJECTIVE:To estimate the costs of treatment including the resources used by patients wit...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-016-0272-z
更新日期:2017-02-01 00:00:00
abstract:BACKGROUND:When pharmaceuticals are administered based on patient characteristics (for example weight or body surface area), an amount of product will be unused and must be disposed of. This wastage represents inefficiency and can distort decision making. METHODS:We present a method for the analysis of optimum fill vo...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-018-0444-0
更新日期:2019-06-01 00:00:00
abstract:BACKGROUND:Patients with venous thromboembolism (VTE) commonly have an underlying genetic predisposition. However, genetic tests nowadays in use have very low sensitivity for identifying subjects at risk of VTE. Thrombo inCode(®) is a new genetic tool that has demonstrated very good sensitivity, thanks to very good cov...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-015-0153-x
更新日期:2015-04-01 00:00:00
abstract::Economic models are developed to provide decision makers with information related to the real-world effectiveness of therapeutics, screening and diagnostic regimens. Although compliance with these regimens often has a significant impact on real-world clinical outcomes and costs, compliance and persistence have histori...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/BF03261872
更新日期:2012-11-01 00:00:00
abstract::Healthcare reforms aim to change certain parts of the health system to improve quality of care, access, or financial sustainability. Traditionally, healthcare reform is understood as an action undertaken by a government at a national or local level. However, bottom-up changes can also lead to improvements in the healt...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-017-0315-0
更新日期:2017-12-01 00:00:00
abstract:BACKGROUND:Liposomal amphotericin B (L-AMB) and amphotericin B lipid complex (ABLC) are both indicated for treating invasive fungal infections (IFIs) caused by Aspergillus, Candida and Cryptococcus spp. among patients who are refractory to or intolerant of conventional amphotericin B (CAB). Prior studies have suggested...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-013-0072-7
更新日期:2014-02-01 00:00:00
abstract:BACKGROUND:The clinical management of intracranial aneurysms is debated in many countries because of the associated disability risk and costs. Therefore, estimating the costs and explaining their variability will provide important information for decision makers. OBJECTIVE:We aimed to evaluate the acute and post-acute...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-013-0041-1
更新日期:2013-08-01 00:00:00
abstract::The rapid rise in pharmaceutical costs in France has been driven by new technologies and the growing prevalence of chronic diseases as well as considerable prescribing freedom and choice of physician among patients. This has led to the introduction of a number of reforms and initiatives in an attempt to moderate expen...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/BF03256162
更新日期:2010-01-01 00:00:00
abstract::One focus of health economics is the trade-off between limited resources and the (health) needs of a community. Cost-effectiveness analysis (CEA), while being one of the most accepted evaluation methodologies in health economics, does not account for many important costs and benefits of health care interventions. Some...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:
更新日期:2003-01-01 00:00:00
abstract:INTRODUCTION:From 2000 to 2004, primary care organisations (PCOs) in England were legally required to operate a prescribing incentive scheme for their general practices. A statutory framework specified the types of target, maximum rewards and use of 'good cause for failure' provisions that schemes should include. Our o...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/00148365-200504020-00005
更新日期:2005-01-01 00:00:00
abstract:BACKGROUND:Antiplatelet therapy plays a central role in the prevention of atherothrombotic events. Both acetylsalicylic acid (aspirin) and clopidogrel have been shown to reduce the risk of recurrent cardiovascular events in various subgroups of patients with vascular disease. OBJECTIVE:To estimate the cost effectivene...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/11535520-000000000-00000
更新日期:2010-01-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:Generic substitution has been introduced in most countries in order to reduce costs and improve access to drugs. However, regulations and the generic drugs available vary between countries. It is the prescriber or dispenser of the drug who is the final decision maker. Nevertheless, physicians'...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-014-0145-2
更新日期:2015-08-01 00:00:00
abstract::This article reviews the concept of costing, and how cost data have been considered and reported in recent multinational economic evaluations. It appears that current practice frequently does not comply with microeconomic foundations and standards for good practice. A number of studies fail to indicate the year of cos...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:
更新日期:2003-01-01 00:00:00
abstract:BACKGROUND AND OBJECTIVE:Opinions on the use of research abstracts in policy decision making are conflicting. We sought to evaluate the influence of research abstracts in guiding decisions of the Joint Oncology Drug Review of Canada (JODR), which conducts clinical and economic reviews of new cancer treatment drugs for ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/11530510-000000000-00000
更新日期:2010-01-01 00:00:00
abstract::The mandatory nature of recommendations made by the National Institute for Health and Clinical Excellence (NICE) in the UK has highlighted inherent difficulties in the process of disinvestment in existing technologies to fund NICE-approved technologies. A lack of evidence on candidate technologies means that the proce...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/BF03256137
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:Low back pain (LBP) is a major health problem, having a substantial effect on peoples' quality of life and placing a significant economic burden on healthcare systems and, more broadly, societies. Many interventions to alleviate LBP are available but their cost effectiveness is unclear. OBJECTIVES:To identi...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-016-0268-8
更新日期:2017-04-01 00:00:00
abstract:BACKGROUND:Although suicide-prevention campaigns have been implemented in numerous countries, Canada has yet to implement a strategy nationally. This is the first study to examine the cost utility of the implementation of a multidimensional suicide-prevention program that combines several interventions over a 50-year t...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-019-00511-5
更新日期:2020-04-01 00:00:00
abstract::Payment incentives to both consumers and providers have significant consequences for the equity and efficiency of a healthcare system, and have recently come to the fore in health policy reforms. This review first discusses the economic rationale for the apparent international convergence toward payment systems with m...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/00148365-200403010-00009
更新日期:2004-01-01 00:00:00
abstract::Smoking of tobacco products is a major public health challenge in prison settings in most countries. Although tobacco use was tolerated by custodial authorities for many decades, the overwhelming evidence of the adverse public health effects of tobacco on both the smokers and those in the vicinity of exhaled or passiv...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:
更新日期:2002-01-01 00:00:00
abstract:BACKGROUND:In virologically suppressed patients, switching to darunavir/ritonavir (DRV/r) monotherapy maintains HIV RNA suppression, and could also lower treatment costs. OBJECTIVE:The purpose of this analysis was to calculate the potential cost savings from the use of DRV/r monotherapy in the UK. METHODS:In the MONE...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,随机对照试验
doi:10.2165/11592220-000000000-00000
更新日期:2011-07-01 00:00:00
abstract:BACKGROUND:South Korea is unique in that it leads global markets in R&D as well as production of biosimilar products and was the first market into which some biosimilar products were introduced. We analyzed the time trend of market penetration and simulated saved spending by biosimilars in South Korea. METHODS:We pull...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-019-00547-7
更新日期:2020-08-01 00:00:00
abstract:BACKGROUND:The Xpert® MTB/RIF (Xpert) test has been shown to be effective and cost-effective for diagnosing tuberculosis (TB) under conditions with high HIV prevalence and HIV-TB co-infection but less is known about Xpert's cost in low HIV prevalence settings. Cambodia, a country with low HIV prevalence (0.7%), high TB...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-018-0397-3
更新日期:2018-08-01 00:00:00
abstract:BACKGROUND:Price, income and health status are likely to affect the demand for healthcare in developing countries, and their quantitative effects are unclear in the literature. Some studies report that prices are not important determinants, while others conclude that prices are important determinants of the demand for ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/BF03256160
更新日期:2009-01-01 00:00:00
abstract:OBJECTIVES:The objective of this study was to construct an early economic evaluation for acalabrutinib for relapsed chronic lymphocytic leukaemia (CLL) to assist early reimbursement decision making. Scenarios were assessed to find the relative impact of critical parameters on incremental costs and quality-adjusted life...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-019-00496-1
更新日期:2019-12-01 00:00:00